Skip to main content
IL DONG PHARMACEUTICAL CO., LTD. logo

IL DONG PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 249420 ISIN · KR7249420001 KO Manufacturing
Open in API
Filings indexed 393 across all filing types
Latest filing 2024-04-04 Major Shareholding Noti…
Country KR South Korea
Listing KO 249420

About IL DONG PHARMACEUTICAL CO., LTD.

https://mobile.ildong.com/eng/main/main…

IL DONG PHARMACEUTICAL CO., LTD. is a pharmaceutical company engaged in the research, development, manufacturing, and commercialization of a broad range of healthcare products. The company's portfolio encompasses ethical drugs, over-the-counter (OTC) medications, active pharmaceutical ingredients (APIs), and health functional foods. Key therapeutic areas of focus include metabolic disorders, gastrointestinal diseases, degenerative diseases, oncology, and cardiovascular conditions. Its robust research and development pipeline features promising drug candidates such as an oral GLP-1 receptor agonist for diabetes and obesity, a P-CAB class treatment for peptic ulcers, and a first-in-class CXCR7 agonist for fibrotic diseases. Utilizing its GMP-certified facilities, the company also offers contract manufacturing (CMO) services, with specialized capabilities in antibiotics and oncology drugs, while actively pursuing global expansion through strategic partnerships and licensing.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서), which is a standard regulatory filing in South Korea (often referred to as a 5% report). It details changes in share ownership by major shareholders and special related parties, including reasons for changes such as the retirement of executives. This falls under the category of 'Major Shareholding Notification' (MRQ) as it tracks significant ownership levels and changes in shareholding status.
2024-04-04 Korean
최대주주등소유주식변동신고서
Director's Dealing Classification · 100% confidence The document is a 'Report of Change in Shareholding by Major Shareholders and Related Parties' (최대주주등소유주식변동신고서) for Ildong Pharmaceutical. It details specific changes in share ownership for individuals (directors/executives) and entities, including reasons for changes such as 'resignation of executive' (임원퇴임). This falls under the category of Director's Dealing (DIRS) as it reports personal share transactions and changes in holdings by company insiders and major shareholders.
2024-04-04 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official report of the results from a General Meeting of Shareholders (AGM). It details the approval of financial statements, dividend status, and the election of directors (board members). This aligns perfectly with the definition of a Declaration of Voting Results & Voting Rights Announcement (DVA), as it provides the outcome of the shareholder votes held on 2024-03-22.
2024-03-22 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 100% confidence The document is a formal regulatory filing titled '사외이사의 선임ㆍ해임 또는 중도퇴임에 관한 신고' (Report on the Appointment, Dismissal, or Resignation of Outside Directors). It details the appointment of a new outside director, including their name, background, and term of office. This falls under the category of Board/Management Information, as it specifically concerns changes to the composition of the board of directors.
2024-03-22 Korean
사업보고서 (2023.12)
Audit Report / Information Classification · 100% confidence The document is a formal 'Audit Report' (감사보고서) for Ildong Pharmaceutical Co., Ltd. for the fiscal year ending December 31, 2023. It includes the independent auditor's report, financial statements (Statement of Financial Position, Statement of Comprehensive Income, Statement of Changes in Equity, Statement of Cash Flows), and detailed notes. It is not an Annual Report (10-K) as it focuses specifically on the audit and financial statements rather than the full narrative business report, and it is not an announcement (RPA) because it contains the full financial data. FY 2023
2024-03-14 Korean
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a regulatory filing from Ildong Pharmaceutical titled 'Audit Report Submission' (감사보고서 제출). It provides a summary of the audit opinion (unqualified/proper) and key financial data (assets, liabilities, profit/loss) for both consolidated and separate financial statements. While it contains financial data, it is a formal notification of the audit report's completion and submission to the regulator, rather than the full annual report itself. According to the 'Menu vs Meal' rule, this is a report publication announcement regarding the audit results. FY 2023
2024-03-14 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.